380 related articles for article (PubMed ID: 28570035)
21. Modeling K-Ras-driven lung adenocarcinoma in mice: preclinical validation of therapeutic targets.
Drosten M; Barbacid M
J Mol Med (Berl); 2016 Feb; 94(2):121-35. PubMed ID: 26526121
[TBL] [Abstract][Full Text] [Related]
22. Molecular spectrum of somatic EGFR and KRAS gene mutations in non small cell lung carcinoma: determination of frequency, distribution pattern and identification of novel variations in Indian patients.
Das BR; Bhaumik S; Ahmad F; Mandsaurwala A; Satam H
Pathol Oncol Res; 2015 Jul; 21(3):675-87. PubMed ID: 25637496
[TBL] [Abstract][Full Text] [Related]
23. Clinical features and therapeutic options in non-small cell lung cancer patients with concomitant mutations of EGFR, ALK, ROS1, KRAS or BRAF.
Zhuang X; Zhao C; Li J; Su C; Chen X; Ren S; Li X; Zhou C
Cancer Med; 2019 Jun; 8(6):2858-2866. PubMed ID: 31016879
[TBL] [Abstract][Full Text] [Related]
24. Clinical outcome with platinum-based chemotherapy in patients with advanced nonsquamous EGFR wild-type non-small-cell lung cancer segregated according to KRAS mutation status.
Metro G; Chiari R; Bennati C; Cenci M; Ricciuti B; Puma F; Flacco A; Rebonato A; Giannarelli D; Ludovini V; Bellezza G; Ferolla P; Minotti V; Crinò L
Clin Lung Cancer; 2014 Jan; 15(1):86-92. PubMed ID: 24139827
[TBL] [Abstract][Full Text] [Related]
25. Predictive value of oncogenic driver subtype, programmed death-1 ligand (PD-L1) score, and smoking status on the efficacy of PD-1/PD-L1 inhibitors in patients with oncogene-driven non-small cell lung cancer.
Ng TL; Liu Y; Dimou A; Patil T; Aisner DL; Dong Z; Jiang T; Su C; Wu C; Ren S; Zhou C; Camidge DR
Cancer; 2019 Apr; 125(7):1038-1049. PubMed ID: 30548240
[TBL] [Abstract][Full Text] [Related]
26. Co-occurring KRAS mutation/LKB1 loss in non-small cell lung cancer cells results in enhanced metabolic activity susceptible to caloric restriction: an in vitro integrated multilevel approach.
Caiola E; Falcetta F; Giordano S; Marabese M; Garassino MC; Broggini M; Pastorelli R; Brunelli L
J Exp Clin Cancer Res; 2018 Dec; 37(1):302. PubMed ID: 30514331
[TBL] [Abstract][Full Text] [Related]
27. Molecular alterations in non-small cell lung carcinomas of the young.
VandenBussche CJ; Illei PB; Lin MT; Ettinger DS; Maleki Z
Hum Pathol; 2014 Dec; 45(12):2379-87. PubMed ID: 25288236
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathologic characteristics of EGFR, KRAS, and ALK alterations in 6,595 lung cancers.
Lee B; Lee T; Lee SH; Choi YL; Han J
Oncotarget; 2016 Apr; 7(17):23874-84. PubMed ID: 26992209
[TBL] [Abstract][Full Text] [Related]
29. EGFR, KRAS, BRAF, ALK, and cMET genetic alterations in 1440 Sardinian patients with lung adenocarcinoma.
Colombino M; Paliogiannis P; Cossu A; Santeufemia DA; ; Sini MC; Casula M; Palomba G; Manca A; Pisano M; Doneddu V; Palmieri G
BMC Pulm Med; 2019 Nov; 19(1):209. PubMed ID: 31711449
[TBL] [Abstract][Full Text] [Related]
30. Cytomorphological identification of advanced pulmonary adenocarcinoma harboring KRAS mutation in lymph node fine-needle aspiration specimens: Comparative investigation of adenocarcinoma with KRAS and EGFR mutations.
Song DH; Lee B; Shin Y; Choi IH; Ha SY; Lee JJ; Hong ME; Choi YL; Han J; Um SW
Diagn Cytopathol; 2015 Jul; 43(7):539-44. PubMed ID: 25427298
[TBL] [Abstract][Full Text] [Related]
31. Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine.
Aredo JV; Padda SK
Curr Treat Options Oncol; 2018 Jun; 19(8):43. PubMed ID: 29951788
[TBL] [Abstract][Full Text] [Related]
32. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y; Wu BQ; Zhong HH; Hui P; Fang WG
Int J Clin Exp Pathol; 2013; 6(9):1880-9. PubMed ID: 24040454
[TBL] [Abstract][Full Text] [Related]
33. Nonsquamous, Non-Small-Cell Lung Cancer Patients Who Carry a Double Mutation of EGFR, EML4-ALK or KRAS: Frequency, Clinical-Pathological Characteristics, and Response to Therapy.
Ulivi P; Chiadini E; Dazzi C; Dubini A; Costantini M; Medri L; Puccetti M; Capelli L; Calistri D; Verlicchi A; Gamboni A; Papi M; Mariotti M; De Luigi N; Scarpi E; Bravaccini S; Turolla GM; Amadori D; Crinò L; Delmonte A
Clin Lung Cancer; 2016 Sep; 17(5):384-390. PubMed ID: 26712101
[TBL] [Abstract][Full Text] [Related]
34. Targeting the KRAS Pathway in Non-Small Cell Lung Cancer.
Tomasini P; Walia P; Labbe C; Jao K; Leighl NB
Oncologist; 2016 Dec; 21(12):1450-1460. PubMed ID: 27807303
[TBL] [Abstract][Full Text] [Related]
35. KRAS-mutant non-small cell lung cancer: Converging small molecules and immune checkpoint inhibition.
Adderley H; Blackhall FH; Lindsay CR
EBioMedicine; 2019 Mar; 41():711-716. PubMed ID: 30852159
[TBL] [Abstract][Full Text] [Related]
36. [EGFR and KRAS Gene Mutations in 754 Patients with Resectable Stage I-IIIa Non-small Cell Lung Cancer and Its Clinical Significance].
Zhao J; Gao J; Guo L; Hu X; Liu Q; Zhao J; Liu L; Jiang J; Wang M; Liang Z; Xu Y; Chen M; Zhang L; Li L; Zhong W
Zhongguo Fei Ai Za Zhi; 2017 Sep; 20(9):617-622. PubMed ID: 28935015
[TBL] [Abstract][Full Text] [Related]
37. Prognostic value of the KRAS G12V mutation in 841 surgically resected Caucasian lung adenocarcinoma cases.
Renaud S; Falcoz PE; Schaëffer M; Guenot D; Romain B; Olland A; Reeb J; Santelmo N; Chenard MP; Legrain M; Voegeli AC; Beau-Faller M; Massard G
Br J Cancer; 2015 Oct; 113(8):1206-15. PubMed ID: 26372703
[TBL] [Abstract][Full Text] [Related]
38. Survival outcome according to KRAS mutation status in newly diagnosed patients with stage IV non-small cell lung cancer treated with platinum doublet chemotherapy.
Brady AK; McNeill JD; Judy B; Bauml J; Evans TL; Cohen RB; Langer C; Vachani A; Aggarwal C
Oncotarget; 2015 Oct; 6(30):30287-94. PubMed ID: 26471290
[TBL] [Abstract][Full Text] [Related]
39. KRAS and NKX2-1 Mutations in Invasive Mucinous Adenocarcinoma of the Lung.
Hwang DH; Sholl LM; Rojas-Rudilla V; Hall DL; Shivdasani P; Garcia EP; MacConaill LE; Vivero M; Hornick JL; Kuo FC; Lindeman NI; Dong F
J Thorac Oncol; 2016 Apr; 11(4):496-503. PubMed ID: 26829311
[TBL] [Abstract][Full Text] [Related]
40. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs).
Schmid S; Gautschi O; Rothschild S; Mark M; Froesch P; Klingbiel D; Reichegger H; Jochum W; Diebold J; Früh M
J Thorac Oncol; 2017 Apr; 12(4):681-688. PubMed ID: 28007627
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
